Impact of the Microbiota on the Likelihood of Renal Graft Rejection

ConditionKidney Transplant Rejection

Trial statusRecruiting

Trial phaseNot listed

Trial typeObservational

Biological sexAll

Age18-70

SponsorInstitut National de la Santé Et de la Recherche Médicale, France

About this trial

Identification of a bacterial signature in the blood or stool that may be associated with acute rejection in patients treated with Nulojix during their first year of transplant.

Eligibility criteria

Qualifiers

Patients called for a kidney transplant

Induction therapy with Simulect, maintenance therapy with Nulojix, mycophenolate acid and steroids

Patient having signed the informed consent

Disqualifiers

Multiple grafts combined or sequential

Induction therapy with polyclonal antibodies

HIV or active viral infection such as hepatitis B or C

Active bacterial infection

Trial design

Treatments tested in this trial

Belatacept Injection [Nulojix]

Treatment groups

70 Participants

are divided into 1 treatment group

Sponsors and collaborators

Institut National de la Santé Et de la Recherche Médicale, France

Lead sponsor

Source ClinicalTrials.gov